76 research outputs found

    Projected preventive effect of treating earlier into infection (Scenario B).

    No full text
    <p>Panel A): Reduction of anti-HCV antibody prevalence following treatment of 50% of chronically infected cases, 4, 3, 2 and 1 year into infection, and 75% of acute symptomatic cases. Panel B): effect on chronic HCV viremia prevalence. Panel C): new infections averted per every 100 treatment courses initiated.</p

    Projected preventive effect of increasing hepatitis C treatment coverage (Scenario A).

    No full text
    <p>Panel A): Reduction of anti-HCV antibody prevalence following treatment introduction and scale up to a 25%, 50% and 75% coverage level. Panel B): Reduction of prevalence of HCV true viremic chronic infections. Panel C): new infections averted per every 100 treatment courses of chronically infected cases.</p

    Variables and Parameters Estimates.

    No full text
    *<p><i>β</i> range selected to obtain the published range of baseline HCV Ab prevalence.</p>**<p><i>λ<sub>0</sub></i> and <i>λ<sub>M</sub></i> vary with <i>β</i>.</p

    Model schematic.

    No full text
    <p>S: Susceptible individuals; A<sub>A</sub>: Acute asymptomatic cases; A<sub>S</sub>: Acute symptomatic cases; T<sub>A</sub>: Treated Acute symptomatic cases; R: Recovered infections; C: Chronic infections; T<sub>C</sub>: Treated Chronic infections.</p

    MSCs surface markers and odontogenic genes expression of DPSCs cultured on TCPS (tissue culture polystyrene) prior to seeding into bECM hydrogel scaffolds.

    No full text
    <p>(A) Immunophenotype analysis of CD13, CD29, CD44, CD73, CD90, CD105, CD146, CD45 and HLA-DR expression in DPSCs by flow cytometry. The green histograms represent the cell count for the specific antibody, and the blue histograms represent the fluorescence of the negative control. The percentage of cells positive for each antigen is shown in the figure. (B) Phase contrast and Von Kossa staining of human DPSCs cultured on TCPS and maintained in basal or osteo/odontogenic medium for 3 weeks (dark color indicates mineral nodules), scale bar: 100 μm. OM: osteo/odontogenic medium. (C) qRT-PCR at 3 weeks for odontogenic markers DSPP, DMP-1 and MEPE of DPSCs seeded on TCPS cultured in basal medium compared to those cultured in osteo/odontogenic medium. The results are presented as the fold increase (2<sup>-(ΔΔCT)</sup>) with respect to the level expressed in DPSCs cultured in basal medium. All values are expressed as the means ± SDs and were normalised to HPRT expression levels, comparison by unpaired two-tailed Student’s t-test. *<i>P</i> < 0.05. OM: osteo/odontogenic medium.</p

    Morphology and odontogenic gene expression of DPSCs on bECM or Col-I hydrogel scaffolds cultured in medium containing odontogenic inducers.

    No full text
    <p>(A) Representative images of human DPSCs cultured on 4 mg/ml bECM or 4 mg/ml Col-I hydrogel scaffolds in osteo/odontogenic medium (OM) for 3 weeks, scale bar: 100 μm. (B) qRT-PCR at 3 weeks for odontogenic markers DSPP, DMP-1 and MEPE of DPSCs seeded on 4 mg/ml bECM hydrogel scaffold, 4 mg/ml Col-I or TCPS cultured in osteo/odontogenic medium. The results are presented as the fold increase (2<sup>-(ΔΔCT)</sup>) with respect to the level expressed in DPSCs seeded on TCPS cultured in osteo/odontogenic medium. The data shown are the means ± SDs of three independent experiments, *<i>P</i> < 0.05, ** <i>P</i> < 0.01 compared with DPSCs cultured osteo/odontogenic medium or 4 mg/ml bECM cultured in basal medium. OM: osteo/odontogenic medium.</p

    Cell morphology, mineralization and relative mRNA expression of odontogenic genes in DPSCs cultured on bECM or Col-I hydrogel scaffolds in normal culture conditions.

    No full text
    <p>(A) Representative images of human DPSCs cultured on bECM hydrogel scaffolds (3, 4, 6, 8 mg/ml) or Col-I hydrogel scaffolds (3, 4, 6, 8 mg/ml) in basal medium for 3 weeks, scale bar: 100 μm. (B) qRT-PCR at 3 weeks for odontogenic markers DSPP, DMP-1 and MEPE of DPSCs seeded on bECM (3, 4, 6, 8 mg/ml), Col-I (3, 4, 6, 8 mg/ml) hydrogel scaffolds or TCPS cultured in basal medium compared to those seeded on TCPS in presence of osteo/odontogenic medium (OM). The results are presented as the fold increase (2<sup>-(ΔΔCT)</sup>) with respect to the level expressed in DPSCs seeded on TCPS cultured in basal medium. All values are expressed as the means ± SDs and were normalised to HPRT expression levels, comparison by unpaired two-tailed Student’s t-test. *<i>P</i> < 0.05, **<i>P <</i> 0.01. (C) Von Kossa staining of human DPSCs cultured on bECM (3, 4, 6, 8 mg/ml) and Col-I (3, 4, 6, 8 mg/ml) hydrogel scaffolds in basal medium for 3 weeks. Black color indicates mineral deposition. Scale bar: 100 μm.</p

    Model structure for the natural history of human papillomavirus infection and cervical cancer.

    No full text
    <p>The model structure reflects the natural history of HPV infection towards cervical cancer. Women can be infected by HPV and progress to low-grade CIN or high-grade CIN, or regress with natural immunity. Low-grade CIN progress to high-grade CIN, or regress thanks to the natural immunity. High-grade CIN progress to invasive cervical cancer (local, regional and distant cancer), or regress thanks to the natural immunity. In the male model, there are three compartments considered: susceptibility to infection, infection and recovery with natural immunity. Female can be protected by HPV vaccine.</p
    corecore